Prostate Cancer | Specialty

Dr. Ryan on the Unblinding of the COU-AA-302 Trial

August 13th 2012

Dr. Charles Ryan from the UCSF Helen Diller Family Comprehensive Cancer Center Discusses the Unblinding of the COU-AA-302 Trial

Urology Practice Management Peer Exchange

August 10th 2012

Investigating Large and Small Urology Practice Intricacies

August 10th 2012

Balancing Quality of Care and Costs in Urology Practices

August 10th 2012

Physician Extenders in Urology Practices, Part I

August 10th 2012

Bone Health Programs in Urology Practices, Part II

August 10th 2012

Introduction to Urologists in Cancer Care Peer Exchange

August 10th 2012

Bone Health Programs in Urology Practices, Part I

August 10th 2012

Management of Oncology Care in Urology Practices

August 10th 2012

Physician Extenders in Urology Practices, Part II

August 10th 2012

Study Supporting Lower Threshold on PSA Risk Levels Wins Award

August 6th 2012

Men with a baseline PSA between 1.5 and 4.0 ng/mL faced a 15-fold increase in prostate cancer over a four-year period as compared with men whose baseline PSA levels were

Abiraterone Acetate Significantly Improves PFS in Metastatic Prostate Cancer

August 3rd 2012

An interim analysis of the COU-AA-302 trial investigating the use of abiraterone acetate (Zytiga) in chemotherapy-naïve patients with mCRPC showed a trend toward improvement in PFS and OS.

Leading Enzalutamide Investigator Offers Insights Into Pivotal Data

August 1st 2012

Since the phase III AFFIRM trial of enzalutamide was halted after meeting its endpoint of improved OS, physicians have remained hopeful about its potential as a treatment for prostate cancer.

Heat-Shock Protein Inhibitor Delays Disease Progression in Phase II Trial

July 26th 2012

The novel agent OGX-427 delayed disease progression in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer, according to the preliminary results.

Sipuleucel-T Studies Support Earlier Use, Reveal Potential Biomarker

July 25th 2012

Research presented at ASCO 2012 examined the expanded use of sipuleucel-T, as well as methods to determine which patients might benefit the most from the therapy.

Black Men With Advanced Prostate Cancer May Benefit From Sipuleucel-T

July 18th 2012

Preliminary data suggest a promising role for sipuleucel-T as a treatment for African-American men with metastatic castration-resistant prostate cancer (mCRPC).

Dr. Taplin on Abiraterone Acetate's Mechanism of Action

July 17th 2012

Dr. Mary-Ellen Taplin, from the Dana-Farber Cancer Institute, on Abiraterone Acetate's Mechanism of Action

Healthy Lifestyle Improves Sexual Function Post-Prostatectomy

July 17th 2012

Patients with prostate cancer can expect better sexual function after a robotic-assisted radical prostatectomy (RARP) if they maintain a healthy lifestyle.

The Urology Group: Balancing Expansion With Commitment to the Community

July 13th 2012

In tough economic times when many medical practices have scaled back or even shut down, The Urology Group has flourished.

Bone Health Programs in Urology Practices Deliver Continuity of Care

July 12th 2012

Spurred by the desire to provide the full spectrum of care to prostate cancer patients, urologists across the country have begun to integrate bone health clinics into their practices.